210 related articles for article (PubMed ID: 33332479)
1. Tegoprazan to treat gastroesophageal reflux disease.
Mermelstein J; Mermelstein AC; Chait MM
Drugs Today (Barc); 2020 Nov; 56(11):715-721. PubMed ID: 33332479
[TBL] [Abstract][Full Text] [Related]
2. Effects of Tegoprazan, a Novel Potassium-Competitive Acid Blocker, on Rat Models of Gastric Acid-Related Disease.
Kim DK; Lee KH; Kim SJ; Kim SJ; Lee SJ; Park CH; Kim BT; Song GS; Moon BS; Ryu SY
J Pharmacol Exp Ther; 2019 Jun; 369(3):318-327. PubMed ID: 30894456
[TBL] [Abstract][Full Text] [Related]
3. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.
Takahashi N; Take Y
J Pharmacol Exp Ther; 2018 Feb; 364(2):275-286. PubMed ID: 29180359
[TBL] [Abstract][Full Text] [Related]
4. Tegoprazan as a New Remedy for Gastrointestinal Diseases in Comparison with its Therapeutic Predecessors: A Mini-Review.
Anik AH; Proma FA; Saha P; Sarker S
Curr Drug Res Rev; 2023 Apr; ():. PubMed ID: 37132138
[TBL] [Abstract][Full Text] [Related]
5. Review of the clinical development of fexuprazan for gastroesophageal reflux-related disease.
Ramani A; Merchant A; Cash BD
Eur J Clin Pharmacol; 2023 Aug; 79(8):1023-1029. PubMed ID: 37344679
[TBL] [Abstract][Full Text] [Related]
6. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
7. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Chapelle N; Ben Ghezala I; Barkun A; Bardou M
Expert Opin Pharmacother; 2021 Feb; 22(2):219-227. PubMed ID: 32893683
[TBL] [Abstract][Full Text] [Related]
8. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
[TBL] [Abstract][Full Text] [Related]
9. Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.
Kim SH; Cho KB; Chun HJ; Lee SW; Kwon JG; Lee DH; Kim SG; Jung HY; Kim JW; Lee JS; Park H; Choi SC; Jee SR; Kim HS; Ko KH; Park SJ; Lee YC; Park SH; Kim AR; Kim EJ; Park HW; Kim BT; Song GS
Aliment Pharmacol Ther; 2021 Aug; 54(4):402-411. PubMed ID: 34227708
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics of tegoprazan and revaprazan after single and multiple oral doses in healthy subjects.
Sunwoo J; Ji SC; Oh J; Ban MS; Nam JY; Kim B; Song GS; Yu KS; Jang IJ; Lee S
Aliment Pharmacol Ther; 2020 Dec; 52(11-12):1640-1647. PubMed ID: 33131095
[TBL] [Abstract][Full Text] [Related]
11. Proton pump inhibitors in the management of gastroesophageal reflux disease.
Hrelja N; Zerem E
Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
13. Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases.
Inatomi N; Matsukawa J; Sakurai Y; Otake K
Pharmacol Ther; 2016 Dec; 168():12-22. PubMed ID: 27514776
[TBL] [Abstract][Full Text] [Related]
14. Randomised clinical trial: safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of tegoprazan (CJ-12420), a novel potassium-competitive acid blocker, in healthy male subjects.
Han S; Choi HY; Kim YH; Nam JY; Kim B; Song GS; Lim HS; Bae KS
Aliment Pharmacol Ther; 2019 Oct; 50(7):751-759. PubMed ID: 31437865
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis of Potassium-Competitive Acid Blocker-Resistant Non-Erosive Reflux Disease.
Kawami N; Hoshino S; Hoshikawa Y; Takenouchi N; Umezawa M; Hanada Y; Kaise M; Iwakiri K
Digestion; 2018; 98(3):194-200. PubMed ID: 29870976
[TBL] [Abstract][Full Text] [Related]
16. Factors Associated with Potassium-Competitive Acid Blocker Non-Response in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.
Okuyama M; Nakahara K; Iwakura N; Hasegawa T; Oyama M; Inoue A; Ishizu H; Satoh H; Fujiwara Y
Digestion; 2017; 95(4):281-287. PubMed ID: 28501868
[TBL] [Abstract][Full Text] [Related]
17. Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E; Kim S; Kim B; Kim B; Kim Y; Park SS; Song GS; Yu KS; Jang IJ; Lee S
Br J Clin Pharmacol; 2022 Jul; 88(7):3288-3296. PubMed ID: 35146797
[TBL] [Abstract][Full Text] [Related]
18. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
19. Acid-suppressive drugs: A systematic review and network meta-analysis of their nocturnal acid-inhibitory effect.
Zou S; Ouyang M; Cheng Q; Shi X; Sun M
Pharmacotherapy; 2024 Feb; 44(2):171-183. PubMed ID: 38049205
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Lee KJ; Son BK; Kim GH; Jung HK; Jung HY; Chung IK; Sung IK; Kim JI; Kim JH; Lee JS; Kwon JG; Park JH; Huh KC; Park KS; Park MI; Kim N; Lee OY; Jee SR; Lee SK; Youn SJ; Kim SK; Lee ST; Hong SJ; Choi SC; Kim TN; Youn YH; Park HJ; Kang MJ; Park CH; Kim BT; Youn S; Song GS; Rhee PL
Aliment Pharmacol Ther; 2019 Apr; 49(7):864-872. PubMed ID: 30843245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
